Retinal pigment epithelial cell replacement therapy (Cell Cure Neurosciences)
- Generic Name
- Retinal pigment epithelial cell replacement therapy (Cell Cure Neurosciences)
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
Phase 1
Active, not recruiting
- Conditions
- Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06674993
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette)
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05626114
- Locations
- 🇮🇱
Hadassah MC, Jerusalem, Israel
🇮🇱Tel Aviv Sourasky MC, Tel Aviv, Israel
🇺🇸Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
Phase 1
Active, not recruiting
- Conditions
- Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT02286089
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath